GlassScriptPhysician profile
Jesse T Doers
NPI 1467498097
$5,466.36
in general payments reported to CMS, 2019-2025
28 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $230 · 2021: $230 · 2022: $805 · 2023: $1,379 · 2024: $689 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,908.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,050.06 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Amgen INC. | $788.95 | 2023-2025 | Tezspire |
| Janssen Pharmaceuticals, INC | $500.99 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $232.55 | 2019 | |
| Pfizer INC. | $172.94 | 2019-2023 | |
| Insmed, INC. | $170.21 | 2019 | |
| Electromed, INC. | $160.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $159.39 | 2024-2025 | Dupixent |
| Inari Medical, INC. | $146.63 | 2022 | |
| Abbott Laboratories | $145.98 | 2025 | 2nd Gen Centrimag Primary Console |
| Glaxosmithkline, LLC. | $121.35 | 2024 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.29 | 2019-2021 | |
| Pulmonx Corporation | $104.27 | 2022-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Mallinckrodt Hospital Products INC. | $92.30 | 2021 | |
| Grifols USA, LLC | $84.75 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $82.75 | 2019 | |
| Csl Behring | $65.28 | 2023 | Kcentra |
| Intuitive Surgical, INC. | $51.54 | 2022 | |
| Genzyme Corporation | $48.20 | 2024-2025 | |
| Gilead Sciences, INC. | $32.94 | 2019 | |
| Inogen, INC. | $25.05 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Alexion Pharmaceuticals, INC. | $20.97 | 2022 | |
| Portola Pharmaceuticals, LLC | $19.34 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.05 | 2020 | |
| Ucb, INC. | $17.69 | 2023 | Briviact |
| Merck Sharp & Dohme LLC | $17.01 | 2025 | Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $16.98 | 2019 | |
| Abbvie INC. | $15.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Doers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.